Invivyd Announces Positive Phase 3 Results for VYD2311 COVID-19 Treatment
Invivyd (NASDAQ:IVVD) announced favorable Phase 3 analysis for its monoclonal antibody candidate VYD2311, used for treating and preventing COVID-19. The company plans to expand the study by 500 subjects, which may delay top-line results to Q3 2026. Additionally, Invivyd is advancing VMS063, a new monoclonal antibody for measles, with IND readiness expected by late 2026.
Topics: clinical trials covid-19 treatment drug development measles treatment monoclonal antibodies